Insulin Aspart (Novolog) Injectable U-100, U-200 Suppliers & Bulk Manufacturers
Available Forms: Vials/pens
Available Strengths: U-100, U-200
Reference Brands: Novolog, Fiasp(US &EU)
Category: Diabetes
Insulin Aspart (Novolog) is a rapid-acting insulin that mimics natural insulin release after meals. It quickly lowers blood sugar levels, providing flexible timing for meals. Its benefits include rapid onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy in both type 1 and type 2 diabetes management.
Product Description:
Insulin Aspart (Novolog) is a rapid-acting insulin approved in the EU and US for controlling blood glucose during meals. In the EU, Novo Nordisk’s Novolog and Fiasp are regulated by the EMA, with dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, the FDA has approved NovoLog and Fiasp based on comprehensive clinical data and biosimilarity studies, ensuring quality and consistency. Both regions require detailed regulatory dossiers and ongoing pharmacovigilance for safety monitoring. For expert assistance with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.
Insulin Aspart (Novolog) Injectable — third party manufacturing & bulk supply
Insulin Aspart (Novolog) Injectable U-100, U-200 is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Insulin Aspart (Novolog) Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Insulin Aspart (Novolog) Injectable →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Insulin Aspart is used to improve blood sugar control in patients with diabetes mellitus, including both type 1 and type 2 diabetes. It helps regulate glucose levels by allowing sugar to enter cells where it is used for energy.
Insulin Aspart is a rapid-acting recombinant insulin analog produced using biotechnology. It is structurally modified from human insulin to allow faster absorption and quicker onset of action.
Common trade names include NovoLog, NovoRapid, Fiasp, and Trurapi.
The original insulin aspart products NovoLog and NovoRapid were developed and marketed by the pharmaceutical company Novo Nordisk, while other pharmaceutical companies manufacture biosimilar versions.
The generic name is Insulin Aspart.
Common brand names include NovoLog, NovoRapid, Fiasp, and Trurapi.
Insulin Aspart is manufactured in several countries including Denmark, the United States, and other regions by different pharmaceutical manufacturers.
Related Products
Pioglitazone Hydrochloride 150Mg Tablet
Strength:
15 mg, 30 mg, 45 mg
Form: Tablets
Reference Brands: Actos (USA)
View Details
Nateglinide
Strength:
60 mg, 120 mg, 180 mg
Form: Tablets
Reference Brands: Starlix (USA)
View Details
Miglitol
Strength:
25 mg, 50 mg, 100 mg
Form: Tablets
Reference Brands: Glyset (USA), Diastabol (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
